Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Science Matters: A Tantalizing Genomics Tool

This article was originally published in Start Up

Executive Summary

A recent paper in Science demonstrates the power of a chemical genomics-based Connectivity Map to identify the underlying mechanisms--in some cases surprising ones--of experimental drugs. Using this publicly available tool, drug developers may be able to get new information about the potential mechanism of action of the hits coming out of their screens

You may also be interested in...

Combining Chemical Genetics and Cancer Immunotherapy

Two years ago, a team at Stanford described a new "chemical genetics" technique--a more precise way to use small molecules to perturb gene products and living systems. Now they have published more data on the system. And of acute interest to drug developers, they have linked the work to therapeutic applications in cancer immunotherapy, showing the ability to regulate secreted proteins such as IL-2 and TNF.

Surmises from Studying DNA Damage: A Link to Type 2 Diabetes?

Researchers recently catalogued over 700 proteins associated with DNA damage and organized many of them into signaling modules. Scientists poring over this intricate data set may get insights into genetic diseases, cancer, and other complex diseases including diabetes. For example, there's a hint that long-term DNA damage affects the insulin pathway, which could revolutionize thinking about diabetes treatment by providing a set of DNA-damage-related drug targets that could stop the loss of insulin signaling and prevent the onset of the disease.

Science Matters: Targeting Heme Trafficking In A Variety Of Diseases

A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts